ZYDUSLIFE Zydus Lifesciences Q3 FY26 results (Oct–Dec 2025) and concall
Zydus Lifesciences delivered a strong Q3 FY26, with consolidated revenues growing 30% YoY to ₹68.6 billion and EBITDA up 31% to ₹18.2 billion, driven by robust performance across all key segments. The company launched new specialty products and secured key regulatory approvals, while managing the impact of exceptional expenses on net profit and anticipating margin adjustments from recent acquisitions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 9.2%, net profit down 37.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 2,621 | 2,516 | 5,820 | 2,588 | 2,871 +10% | 2,284 −9% |
| EBITDA | 942 | 648 | 3,773 | 585 | 1,152 +22% | 199 −69% |
| Net profit | 790 | 471 | 2,814 | 385 | 1,157 +46% | 296 −37% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
